These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 35302596)

  • 1. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
    Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
    Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
    Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
    Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ
    Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
    Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
    BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterisation of pancreatic ductal adenocarcinoma with
    Allen MJ; Zhang A; Bavi P; Kim JC; Jang GH; Kelly D; Perera S; Denroche RE; Notta F; Wilson JM; Dodd A; Ramotar S; Hutchinson S; Fischer SE; Grant RC; Gallinger S; Knox JJ; O'Kane GM
    J Clin Pathol; 2023 Mar; 76(3):158-165. PubMed ID: 34583947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer.
    Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
    JCO Precis Oncol; 2023 Sep; 7():e2300152. PubMed ID: 37944072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
    Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
    Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
    Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
    Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in
    Fusco MJ; Saeed-Vafa D; Carballido EM; Boyle TA; Malafa M; Blue KL; Teer JK; Walko CM; McLeod HL; Hicks JK; Extermann M; Fleming JB; Knepper TC; Kim DW
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer.
    Xu ZH; Wang WQ; Liu L; Lou WH
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188751. PubMed ID: 35732240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
    Baechmann S; Ormanns S; Haas M; Kruger S; Remold A; Modest DP; Kirchner T; Jung A; Werner J; Heinemann V; Boeck S
    BMC Cancer; 2017 May; 17(1):374. PubMed ID: 28549417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
    Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
    Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice.
    Kimura Y; Fukuda A; Ogawa S; Maruno T; Takada Y; Tsuda M; Hiramatsu Y; Araki O; Nagao M; Yoshikawa T; Ikuta K; Yoshioka T; Wang Z; Akiyama H; Wright CV; Takaori K; Uemoto S; Chiba T; Seno H
    Gastroenterology; 2018 Jul; 155(1):194-209.e2. PubMed ID: 29604291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
    Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
    Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic landscape of clinically advanced
    Ashok Kumar P; Serinelli S; Zaccarini DJ; Huang R; Danziger N; Janovitz T; Basnet A; Sivapiragasam A; Graziano S; Ross JS
    Front Oncol; 2023; 13():1169586. PubMed ID: 37404765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.